INCY Stock Recent News

Incyte Corporation (NASDAQ:INCY ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Greg Shertzer - Director of Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research and Development Christiana Stamoulis - Executive Vice President and Chief Financial Officer Matteo Trotta - EVP, Head of U.S. Dermatology Mohamed Issa - EVP, Head of U.S. Oncology Steven Stein - Chief Medical Officer Conference Call Participants Michael Schmidt - Guggenheim David Lebowitz - Citi Andrew Barrons - Leerink Partners Tazeen Ahmad - Bank of America Jessica Fye - JPMorgan Chase Marc Frahm - TD Cowen Vikram Purohit - Morgan Stanley Ash Verma - UBS James Shin - Deutsche Bank Salim Syed - Mizuho Securities Gavin Clark-Gartner - Evercore ISI Jay Olson - Oppenheimer Operator Greetings, and welcome to the Incyte's First Quarter 2025 Earnings Conference and Webcast. At this time, all participants are in a listen-only mode.

Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.

The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Incyte (INCY) came out with quarterly earnings of $1.16 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.64 per share a year ago.

Incyte Corp raised its annual sales forecast for its blood cancer treatment Jakafi on Tuesday, after robust sales of the drug helped it beat Wall Street estimates for quarterly results.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AACR25--Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025.

INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).